GagCM9-Specific CD8+ T Cells Expressing Limited Public TCR Clonotypes Do Not Suppress SIV Replication In Vivo by Vojnov, Lara et al.
GagCM9-Specific CD8
+ T Cells Expressing Limited Public
TCR Clonotypes Do Not Suppress SIV Replication In Vivo
Lara Vojnov
1, Mauricio A. Martins
1, Jorge R. Almeida
2, Zachary Ende
2, Eva G. Rakasz
1,3, Matthew R.
Reynolds
1, Enrique J. Leon
3, Kim L. Weisgrau
3, Benjamin J. Burwitz
1, Joy M. Folkvord
4, Marlon G. Veloso
de Santana
5, Patrı ´cia C. Costa Neves
5, Elizabeth Connick
4, Pamela J. Skinner
6, Emma Gostick
8, David H.
O’Connor
1, Nancy A. Wilson
1, Myrna C. Bonaldo
5, Ricardo Galler
7, David A. Price
8, Danny C. Douek
2,
David I. Watkins
1,3*
1Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America, 2Human Immunology Section,
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 3Wisconsin
National Primate Research Center, Madison, Wisconsin, United States of America, 4University of Colorado Denver School of Medicine, Denver, Colorado, United States of
America, 5Laboratorio de Biologia Molecular de Flavivı ´rus, Instituto Oswaldo Cruz-FIOCRUZ, Rio de Janeiro, Brazil, 6Department of Veterinary and Biomedical Sciences,
University of Minnesota, St. Paul, Minnesota, United States of America, 7Instituto de Tecnologia em Imunobiologicos, Fundac ¸a ˜o Oswaldo Cruz, Rio de Janeiro, Brazil,
8Department of Infection, Immunity and Biochemistry, Cardiff University, Wales, United Kingdom
Abstract
Several lines of evidence suggest that HIV/SIV-specific CD8
+ T cells play a critical role in the control of viral replication.
Recently we observed high levels of viremia in Indian rhesus macaques vaccinated with a segment of SIVmac239 Gag
(Gag45–269) that were subsequently infected with SIVsmE660. These seven Mamu-A*01
+ animals developed CD8
+ T cell
responses against an immunodominant epitope in Gag, GagCM9, yet failed to control virus replication. We carried out a
series of immunological and virological assays to understand why these Gag-specific CD8
+ T cells could not control virus
replication in vivo. GagCM9-specific CD8
+ T cells from all of the animals were multifunctional and were found in the colonic
mucosa. Additionally, GagCM9-specific CD8
+ T cells accessed B cell follicles, the primary residence of SIV-infected cells in
lymph nodes, with effector to target ratios between 20–250 GagCM9-specific CD8
+ T cells per SIV-producing cell.
Interestingly, vaccinated animals had few public TCR clonotypes within the GagCM9-specific CD8
+ T cell population pre-
and post-infection. The number of public TCR clonotypes expressed by GagCM9-specific CD8
+ T cells post-infection
significantly inversely correlated with chronic phase viral load. It is possible that these seven animals failed to control viral
replication because of the narrow TCR repertoire expressed by the GagCM9-specific CD8
+ T cell population elicited by
vaccination and infection.
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Introduction
Human immunodeficiency virus (HIV)- and simian immuno-
deficiency virus (SIV)-specific CD8
+ T cells appear to play an
essential role in reducing peak and chronic phase HIV/SIV
replication. The emergence and expansion of HIV/SIV-specific
CD8
+ T cells coincide with peak viral decline [1–4]. Depletion of
CD8
+ cells in both progressor and elite controller (ECs) rhesus
macaques leads to increased viral replication in most animals [5–
8], and HIV/SIV-specific CD8
+ T cell pressure selects for viral
escape [9–17]. Select MHC class I alleles, HLA-B*27 and –B*57
in humans and Mamu-B*08 and –B*17 in rhesus macaques, are
associated with control of viral replication in vivo [13,18–22].
Recent studies suggest that Gag-specific CD8
+ T cells play a
role in reducing viral replication [23–30]. Some Gag-specific
CD8
+ T cell clones can recognize and suppress viral replication in
SIV-infected CD4
+ T cells in vitro early in the viral life cycle and
prior to viral integration [29]. In contrast, Env-, Tat-, and Nef-
specific CD8
+ T cell clones failed to recognize SIV-infected CD4
+
T cells before twelve hours post-infection when SIV begins to
downregulate surface CD4 and MHC class I molecules [29,31].
Additionally, analysis of approximately 600 HIV-infected patients
in Durban, South Africa demonstrated a significant inverse
correlation between the breadth of Gag-specific CD8
+ T cell
responses and viral load [26]. Individuals making two or more
Gag-specific CD8
+ T cell responses had significantly lower viral
loads than those making one or no Gag-specific CD8
+ T cell
responses. This same study also showed that individuals making
one or more Env-specific CD8
+ T cell response(s) had higher viral
loads than those making no Env-specific CD8
+ T cell responses.
Though these are key observations from vaccine- and antiretro-
viral-naı ¨ve HIV patients, the success of vaccine-elicited Gag-
specific CD8
+ T cell responses to lower viral loads in vivo is less
clear. MHC class I Mamu-A*01
+ rhesus macaques vaccinated with
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temporally controlled viral replication of SIVmac239 infection
[23,30]. Animals vaccinated with Gag alone made high frequency
Mamu-A*01-restricted Gag181–189CM9-specific (GagCM9-specif-
ic) CD8
+ T cell responses post-infection and had low viral loads
until eighty days post-infection when they began to lose control of
viral replication [23]. Additionally, after DNA/Ad5 vaccination
with Gag, Tat, Rev, and Nef, followed by SIVmac239 challenge,
Mamu-A*01
+ animals again made high frequency GagCM9-
specific CD8
+ T cell responses [30]. However, there were no
significant correlations between peak and chronic phase viremia
and the magnitude of Gag- and Nef-specific responses.
The quality of HIV/SIV-specific CD8
+ T cells may be critical
for a successful anti-HIV/SIV immune response. It has been
previously shown that ECs have HIV-specific CD8
+ T cells
capable of multiple functions: degranulation and secretion of one
or more cytokines [32]. Progressors, on the other hand, have a
more limited functional repertoire. Additionally, HIV-specific
CD8
+ T cells from ECs demonstrate superior proliferative
capacity as well as increased cytotoxicity of HIV-infected CD4
+
T cells than HIV-specific CD8
+ T cells from progressors [33–35].
These studies suggest that eliciting multifunctional HIV/SIV-
specific CD8
+ T cells may be critical for a successful vaccine.
The number of public T cell receptor (TCR) clonotypes within
a CD8
+ T cell population may be inversely correlated with viral
load [36]. Public clonotypes are defined as epitope-specific TCRb-
chain amino acid sequences that occur in more than one animal.
Thus, these are shared T cell receptors that represent an extreme
bias in TCR usage. Price et al. analyzed the frequency of public
TCR clonotypes in the GagCM9-specific CD8
+ T cell population
in vaccinated and unvaccinated SIVmac239-infected rhesus
macaques [36]. Vaccinated macaques with low setpoint viral
loads had several public TCR clonotypes within the GagCM9-
specific CD8
+ T cell population after vaccination and infection.
Additionally, this group observed a significantly inverse relation-
ship between the frequency of public TCR clonotypes elicited by
the GagCM9-specific CD8
+ T cell population and chronic phase
viral load in both vaccinated and unvaccinated animals.
In a previous study, we vaccinated seven Mamu-A*01
+ animals
with recombinant Yellow Fever-17D virus containing a portion of
SIVmac239 Gag (rYF-17D/SIVGag45–269) [37]. Animals were
then mucosally challenged between two and four times until
infection with low-dose heterologous SIVsmE660. Although all
animals made high frequency GagCM9-specific CD8
+ T cell
responses, only one animal successfully controlled viral replication.
Our present study, therefore, sought to determine why these high
frequency GagCM9-specific CD8
+ T cells failed to control virus
replication. GagCM9-specific CD8
+ T cells from all animals
appeared to be multifunctional and accessed the primary sites of
SIV infection; however, GagCM9-specific CD8
+ T cells from all
animals expressed a limited public TCR repertoire after
vaccination and infection. In fact, the chronic phase viral load
could be predicted by the breadth of public TCR usage in the
GagCM9-specific CD8
+ T cell population.
Materials and Methods
Animals and vaccination
Indian rhesus macaques (Macaca mulatta) from the Wisconsin
National Primate Research Center were cared for according to the
regulations and guidelines of the University of Wisconsin
Institutional Animal Care and Use Committee, Animal Welfare
Assurance No. A3368-01. Full details of the study (UW-Madison
Animal Care and Use Protocol No. G00578) were approved by
the University of Wisconsin Institutional Animal Care and Use
Committee in accordance with the recommendations of the
Weatherall report. Once infected, animals were singly housed to
prevent cross contamination of SIV infection and spread of
opportunistic infections. Animals were closely monitored daily for
pain or discomfort and treated accordingly by a veterinarian to
ameliorate any suffering. Following progression to AIDS, animals
were humanely euthanized. Animals were typed for MHC class I
alleles Mamu-A*01, Mamu-A*02, Mamu-B*08 and Mamu-B*17 by
sequence-specific PCR [20,38]. We engineered amino acids 45 to
269 of SIVmac239 Gag into YF17D (rYF17D/SIVGag45–269). This
was done as previously described by inserting a yellow fever codon-
optimized sequence between the genes encoding the viralproteins E
and NS1 of yellow fever [37]. All seven animals were subcutane-
ously given either one or two doses of between 2.3610
4 and
2.3610
5 plaque forming units (PFU) of rYF17D/SIVGag45–269.
Additionally one animal, r01056, was primed with 2610
5 colony
forming units (CFU) of rBCG intradermally containing Gag, Nef,
Rev, Tat, and Vif and a second time with 10
7 CFU of oral rBCG
containing Gag, Nef, Rev, Tat ,and Vif.
Virus stocks, SIV challenge and viral sequencing
SIVmac239, GenBank accession no. M33262, was generated as
previously described [39]. Briefly, Vero cells (acquired from
ATCC; no. CCL-81) were transfected with plasmid DNA
encoding the SIV proviral sequences. One day after transfection,
CEMx174 cells (acquired from ATCC; no. CRL-1991) were
added to the Vero cultures. Virus was expanded on CEMx174
cells and cell-free supernatant collected two days after peak
syncytia formation. SIVsmE660 was generated in a similar
manner to SIVmac239, but expanded on fresh peripheral blood
mononuclear cells (PBMC) isolated from naı ¨ve Indian rhesus
macaques. Harvested virus was analyzed by Gag p27 enzyme-
linked immunosorbent assay (ZeptoMetrix Corporation) and
quantitative RT-PCR prior to animal infection and use in ex vivo
studies. Approximately eight weeks post-rYF17D/SIVGag45–269
boost or mock vaccination, animals were challenged intrarectally
with 6610
6 viral particles of SIVsmE660 (225 50% tissue culture
infective dose [TCID50]). Animals were challenged with this dose
and virus every week until infected. Animals were considered SIV
positive after a positive viral load determination and were no
longer challenged. Animals became infected after between 2–4
virus challenges. Bulk viral Sanger sequencing was performed as
previously described [40]. Briefly, vRNA was extracted from
plasma using a Qiagen MinElute kit (Valencia, CA). We used a
Qiagen One Step RT-PCR kit to amplify the region of Gag
containing GagCM9 and its known compensatory mutations. The
RT-PCR conditions for this amplicon was: 50uC for 30 min; 95uC
for 15 min; 45 cycles of 94uC for 30 s, 53uC for 1 min, and 72uC
for 150 s; and 68uC for 20 min. The amplified cDNA was purified
using a Qiagen PCR purification kit. A 3730 DNA analyzer
(Applied Biosystems) sequenced the cDNA and sequences were
assembled using CodonCode Aligner (CodonCode). Pyrosequenc-
ing was performed similarly to previously described methods [41].
Briefly, vRNA was extracted by the same method used for bulk
viral Sanger sequencing. Viral RNA was reverse transcribed and
amplified using the SuperScript III One-Step RT-PCR System
with Platinum Taq High Fidelity (Invitrogen, Carlsbad, CA) and
MID-tagged primers (454-Life Sciences, Branford, CT) spanning
Gag amino acid residues 155–253. The reverse transcription-PCR
conditions were as follows: 50uC for 15 min; 94uC for 2 min; 40
cycles of 94uC for 15 sec, 58uC for 30 sec, and 68uC for 50 sec;
and 68uC for 5 min. Following PCR clean-up and DNA
quantification, amplicons were pooled at equimolar ratios and
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6 copies/l. Emulsion PCR
was performed at 1.5 copies/bead using the GS Junior Titanium
emPCR kit (Lib-A) per manufacturers instructions (Roche,
Indianapolis, IN). 5610
5 enriched DNA beads were sequenced
on a Roche/454 GS Junior.
Viral load analysis
Viral RNA was extracted using guanidine hydrochloride as
previously described [39,42] for EDTA-anticoagulated plasma and
by M48Virus Mini Kit (Qiagen) for virus production assay samples.
Viral RNA was quantified from both plasma and virus production
assay supernatant with forward primer (SIV1552), 59-GTCTG-
CGTCATCTGGTGCATTC-39, reverse primer (SIV1635), 59-
CACTAGCTGTCTCTGCACTATGTGTTTTG-39, and probe,
59-6-carboxyfluorescein-CTTCCTCAGTGTGTTTCACTTTC-
TCTTCTGCG-6-carboxytetramethylrhodamine-39 using the Su-
perScript III Platinum One-Step Quantitative RT-PCR Kit
(Invitrogen) with the LightCycler 1.2 or 480 (Roche) as previously
described [39].
Lymphocyte isolation from gut pinch biopsies
Pinch biopsies were performed as previously described [43].
Briefly, six to eight pinch biopsies of approximately two cubic mm
were collected from the jejunem of rhesus macaques by Fujinon
FG-100PE pediatric gastroscope. The biopsies were incubated
three times in an orbital shaker at 37uC for 30 minutes in
complete RPMI (RPMI 1640 supplemented with 15% fetal bovine
serum, 2 mM L-glutamine, and 50 mg/ml antimycotic/antibiotic-
all purchased from HyClone Laboratories, Inc.) containing 15 mg
of collagenase type II (Sigma)/ml. The supernatant containing
lymphocytes was collected after each incubation period, washed
twice, and pooled. Cells were filtered using a nylon mesh to
remove large debris. Lymphocytes were isolated by overlaying the
cells on an isotonic Percoll (Amersham-Pharmacia) gradient (40%
layered over 90%) and centrifuging for 30 minutes at 800 rpm.
Lymphocytes were collected from the 90%/40% interface using a
transfer pipette and washed with complete RPMI.
In situ lymph node staining
In situ tetramer staining combined with immunohistochemistry
was performed as described previously [44]. Biotinylated Mamu-
A*01 molecules loaded with GagCM9 peptide were purchased
from Immunomics while irrelevant negative control
(FLPSDYFPSV) peptide was obtained from the National Institute
of Allergy and Infectious Diseases. Fresh tissues embedded in low
melt agarose were cut into 200 micron thick sections and
incubated with MHC tetramers at a concentration of 0.5 ug/ml,
mouse anti-CD20 antibodies (Novacastra) diluted 1:200, and rat-
anti-human CD8 antibodies (AbD Serotec) diluted 1:200 in 1 ml
of cold phosphate buffered saline containing 100 mg/ml heparin
(PBS-H) with 2% normal goat serum at 4uC overnight. Sections
were then washed with chilled PBS-H, fixed with 4% parafor-
maldehyde for 2 h at room temperature, and again washed with
PBS-H. Sections were then incubated with rabbit anti-FITC
antibodies (BioDesign) diluted 1:10,000 in blocking solution, and
incubated at 4uC on a rocking platform overnight. Sections were
washed with PBS-H and incubated with Cy3-conjugated goat anti-
rabbit antibodies (Jackson ImmunoResearch) diluted 1:5000, Cy5-
conjugated anti-rat antibodies (Jackson ImmunoResearch) diluted
1:2000, and Alexa 488-conjugated goat anti-mouse antibodies
(Molecular Probes) diluted 1:2000 in blocking solution for 1 to 3
days, washed again, post-fixed with 4% paraformaldehyde for
1 hour, and then mounted on slides with warmed glycerol gelatin
(Sigma) containing 4 mg/ml n-propyl gallate. Stained sections
were imaged using a Fluoview 1000 microscope (Olympus). To
detect SIV RNA-producing cells, four 6 mm tissue sections (each
section approximately 30 microns apart) of snap frozen lymph
node were stained using a riboprobe for full length SIVmac239 as
previously described to detect HIV RNA-producing cells in
humans [45]. All sections were counterstained with CD20
antibody to define follicular regions. All sections were visualized
and positive cells counted and classified as inside or outside of the
follicle. Area for the follicular region, extrafollicular region and
total tissue was determined using Qwin Pro on a Leica DMR
Fluorescent Microscope (Leica). Data were reported as SIV
+ cells
per mm
2 and replicates were combined.
Quantification of tetramer-binding cells in situ
Three-dimensional montage images were created from lymph
node sections stained with tetramers, anti-CD8 antibodies and
anti-CD20 antibodies using a FluoView 1000 confocal microscope
with a 206objective lens and 3 mm z-steps as previously described
[44]. Confocal z-series were collected from approximately 5 mm
from surface of staining to as deep as the CD20 staining
penetrated, approximately 35 mm into the tissue. Each montage
consisted of several 8006800 pixel fields stitched together using
Olympus Fluoview FV1000 software. Fluoview FV1000 software
was also used to delineate follicular and extrafollicular areas and to
count tetramer-binding cells in delineated areas. Follicular areas
were identified using CD20 staining. To prevent bias, the red
tetramer channel was turned off when follicular and extrafollicular
areas were delineated. Areas that showed loosely aggregated B
cells that were ambiguous as to whether the area was a follicle
were not scored. Cell counts were done on single z-scans. While
doing the cells counts, we stepped up and down through the z-
scans to distinguish tops and bottoms of cells from non-specific
background staining. We also stepped up and down through the z-
scans to evaluate the relative abundance and localization of
tetramer positive cells inside of follicles. Image J software was then
used to trace and measure the areas delineated for cell counts. Cell
counts were performed on both Mamu A*01-restricted GagCM9
and negative control Mamu A*01-restricted FLP stained sections.
Immunological assays
Tetramer staining was performed as previously described [30].
Briefly, 5610
5 to 1610
6 fresh, unstimulated PBMC from rhesus
macaques were stained for 1 hour at 37uC with Mamu-A*01-
restricted GagCM9 tetramer labeled with PE or APC (5 mg/ml).
Cells were stained with CD3 FITC (BD Biosciences, clone SP34-2)
and CD8 PerCP (BD Biosciences, clone 53-6.7) for an additional
30 minutes. The cells were then washed twice with FACS buffer
and fixed with 1% paraformaldehyde. Sample data were acquired
using CellQuest Pro software on a SORP BD LSR II equipped
with a 50 mW 405 violet, a 100 mW 488 blue, and a 50 mW 640
red laser and were analyzed by FlowJo 9.1 (TreeStar, Inc.). IFN-c
Enzyme-linked immunospot (ELISPOT) (Mabtech) assays were
performed using freshly isolated PBMC from rhesus macaques as
previously described [46]. Briefly, 1610
5 PBMC per well were
stimulated with peptide in a precoated ELISPOT plate according
to the manufacturer’s instructions and incubated at 37uCi na5 %
CO2 incubator overnight. All tests were performed in duplicate
using individual peptides at 10 mM or peptide pools (10 15-mer
peptides overlapping by 11 amino acids spanning the entire SIV
genome) at 1 mM. Fifteen-mer peptides were provided by the NIH
AIDS Research and Reference Reagent Program (Germantown,
MD). Plates were imaged using an ELISPOT reader (Autoimmun-
Diagnostika), counted by ELISPOT Reader version 4.0 (Auto-
immun-Diagnostika), and analyzed as previously described [30].
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previously described [30,32,47]. Briefly, freshly isolated PBMC
from rhesus macaques were incubated with 5 mM peptide, anti-
CD28 (clone L293; BD Biosciences), anti-CD49d (clone 9g;
Pharmigen), and CD107a PE (clone H4A3; BD Biosciences)
antibodies and 5 mg per test of Brefeldin A and Golgi Stop
overnight at 37uC in a 5% CO2 incubator. Cells were stained for
the surface expression of CD3 PerCP-Cy5.5 (clone SP34; BD
Biosciences), CD8 APC-Cy7 (clone SK1; BD Biosciences), CD14
PE-Texas Red (clone RMO52; Beckman Coulter), and CD19 PE-
Texas Red (clone JA.119; Beckman Coulter), washed twice with
FACS buffer, and fixed with 1% paraformaldehyde. Cells were
then permeabilized with 0.1% Saponin buffer, intracellularly
stained with IFN-c PE-Cy7 (clone 4S.B3; BD Biosciences), TNF-a
Alexa700 (clone MAb11; BD Biosciences), IL-2 APC (clone MQ1-
17H12; BD Biosciences), and MIP-1b FITC (clone 24006; R&D
Systems), washed twice with Saponin buffer, and fixed with 1%
paraformaldehyde. Sample data were acquired using CellQuest
Pro software on a SORP BD LSR II equipped with a 50 mW 405
violet, a 100 mW 488 blue, and a 50 mW 640 red laser and were
analyzed by FlowJo 9.1 (TreeStar, Inc.). Analysis and presentation
of distributions were performed using Pestle and SPICE version
5.1, downloaded from http://exon.niaid.nih.gov/spice [48].
T cell receptor sequencing
T cell receptors were amplified and sequenced as previously
described [36]. GagCM9-specific tetramer-labeled CD8
+ T cells
were sorted viably from frozen PBMC from rhesus macaques into
1.5 mL microtubes containing 150 mL RNAlater (Applied Biosys-
tems). The median number of sorted cells was 400 cells for the post
vaccination time point and 10,000 for the post infection time
point. All expressed TCRb gene products were amplified without
bias using an anchored template-switch RT-PCR (SMARTer
RACE Clontech); amplicons were subcloned in the pGEM-T easy
vector system (Promega) and cloned by transformation of
competent DH5a E. coli (Invitrogen). Selected colonies were
amplified by PCR with standard M13 primers and sequenced
using the Sanger technique. A minimum of 50 clones were
generated and analyzed per sample.
Results
Immunodominant, multifunctional Mamu-A*01-
restricted GagCM9-specific CD8
+ T cells do not control
viral replication
We vaccinated seven Mamu-A*01
+ Indian rhesus macaques with
Yellow Fever-17D expressing amino acids 45 to 269 of the
SIVmac239 Gag protein (rYF-17D/SIVGag45–269) (Table 1). The
SIV transgene was inserted between the YF-17D Envelope and
NS1 genes as detailed previously [37]. Approximately two months
after vaccination, animals were repeatedly challenged with six
million viral copies of the swarm SIVsmE660 virus. It took
between two to four challenges to infect all seven animals. These
animals had an average peak of viral replication at two weeks post
infection of three million viral RNA copies/ml. By thirty-two
weeks post-infection, six of the seven animals had a viral load of
greater than 8,000 viral RNA copies/ml (Figure S1a–g). The
average viral load at thirty-two weeks post-infection was .60,000
viral RNA copies/ml (Figure 1). Only animal r02049 maintained a
viral load below 1,000 viral RNA copies/ml throughout the
chronic phase of infection.
An additional two Mamu-A*01
+ animals, r02109 and r02110,
were vaccinated with empty rYF-17D and subsequently chal-
lenged with SIVsmE660. Neither animal controlled viral replica-
tion under 2,000 viral RNA copies/ml in the chronic phase of
infection (Figure S1h and i). Six of the seven vaccinees had viral
loads comparable to, if not higher, than the two control animals.
The group mean viral load of the vaccinees was similar to the viral
loads of the mock-vaccinated controls (Figure 1), illustrating that
the vaccinated animals failed to control viral replication in vivo.
Throughout infection, we measured the Mamu-A*01-restricted
GagCM9-specific CD8
+ T cell response from all animals using
MHC class I tetramers (Figure S1a–i). Six of the seven vaccinated
animals had a peak of the GagCM9-specific CD8
+ T cell response
at week two or three post-infection that ranged between 2.72–
38.6% of total CD3
+CD8
+ T cells. Both of the mock-vaccinated
controls, r02109 and r02110, also made GagCM9-specific CD8
+
T cell responses post-infection. Animal r02109 had a peak
GagCM9-specific CD8
+ T cell response at week six post-infection
Table 1.
Animal Gender Prime Boost
# of
challenges
MHC class
I alleles
MHC class
II alleles
GagCM9
CD8
+ T cell
avidity (nM)
r01056 M 2.06105 CFU rBCG i.d.,
107 CFU rBCG oral of
GNRTV
2.06105 PFU rYF17D/
SIVGag45–269
3 A*01, B*17,
B*29, B*52
DRB1*0401 32
r02013 F none 2.06105 PFU rYF17D/
SIVGag45–269
4 A*01, B*22 none tested 19
r02042 F 2.36105 PFU rYF17D/
SIVGag45–269
2.06105 PFU rYF17D/
SIVGag45–269
2 A*01, B*22,
B*29, B*30
DPB1*06 7
r02049 M 2.36105 PFU rYF17D/
SIVGag45–269
2.06105 PFU rYF17D/
SIVGag45–269
2 A*01, B*46 DRBw*201,
DPB1*06, DRB1*0303
44
r03130 M 2.36104 PFU rYF17D/
SIVGag45–269
2.06105 PFU rYF17D/
SIVGag45–269
2 A*01, B*29,
B*46
DRB*w201,
DPB1*06
36
r04051 F none 2.06105 PFU rYF17D/
SIVGag45–269
2 A*01, A*08,
B*30, B*46
DRB1*0401, DRB1*
0306, DRB1*1003
73
r04091 M 2.36104 PFU rYF17D/
SIVGag45–269
2.06105 PFU rYF17D/
SIVGag45–269
4 A*01, B*22,
B*30, B*46
DRB*w201,
DPB1*06, DRB1*0303
38
doi:10.1371/journal.pone.0023515.t001
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+CD8
+ T cells (Figure S1h). Animal
r02110, however, maintained its GagCM9-specific CD8
+ T cell
frequency below 1% of total CD3
+CD8
+ T cells throughout
infection (Figure S1i). Overall, vaccinated animals had 3.2 fold
higher peak frequencies of GagCM9-specific CD8
+ T cells than
the control animals (Figure 1). Additionally, the GagCM9-specific
CD8
+ T cells from all animals displayed a high avidity profile
indicating the GagCM9-specific CD8
+ T cells required few MHC-
epitope complexes on the surface of a target cell to induce cytokine
secretion (Table 1). Despite the rapidly induced high frequency
anamnestic GagCM9-specific CD8
+ T cells in the vaccinated
animals, viral replication in six of the seven vaccinated animals was
comparable to the mock-vaccinated controls. Thus, it appeared
the high frequency of the vaccine-induced GagCM9-specific
CD8
+ T cells failed to control viral replication in vivo.
Six out of the seven animals did not control viral replication
even with such high frequency GagCM9-specific CD8
+ T cell
responses. We, therefore, sought to determine why these
GagCM9-specific CD8
+ T cells failed to control viral replication.
First, we tested the multifunctional capacity of chronic phase
GagCM9-specific CD8
+ T cells from our seven animal cohort
using an intracellular cytokine stain assay (ICS) (Figure 2). The
multifunctional capacity of HIV-specific CD8
+ T cells has been
associated with elite control of HIV-infected patients [32]. HIV-
specific CD8
+ T cells that degranulate while concurrently secreting
multiple cytokines have been correlated with low patient viral
loads, while HIV-specific CD8
+ T cells from progressors
consistently failed to perform all five functions and were generally
less multifunctional. We hypothesized that the GagCM9-specific
CD8
+ T cells from these animals might not express an appropriate
range of cytokines and thus could not control viral replication. We,
therefore, compared the cytokine profile of the vaccinated animals
at approximately ten weeks post-infection to a Mamu-A*01
+ delta-
nef-vaccinated, SIVsmE660-infected EC, r88085, which is suc-
Figure 1. Viral load and GagCM9-specific CD8
+ T cell tetramer
staining. The group mean viral load of the vaccinated animals (black
diamonds and connecting lines) was comparable to the two mock-
vaccinated, SIVsmE660-infected control animals (black circles and
connecting lines); however, the vaccinated animals had higher
frequencies of GagCM9-specific CD8
+ T cells (red triangles and
connecting line) than the mock-vaccinated control animals (blue
triangles and connecting line).
doi:10.1371/journal.pone.0023515.g001
Figure 2. Multifunctional GagCM9-specific CD8
+ T cell responses. (a, b) Using intracellular cytokine staining, we analyzed the ability of
GagCM9-specific peptide-stimulated PBMC to degranulate (CD107a) and secrete MIP-1b, TNF-a, IFN-c, and/or IL-2 at week ten post-infection. (a) Bar
graphs indicate the GagCM9-specific CD8
+ T cell response frequency for each molecule alone or in combination with the other tested molecules from
each animal. Each vertical black line below the horizontal colored bars indicates positivity for CD107a, MIP-1b, TNF-a, IFN-c and/or IL-2. (b) Pie graphs
indicate the percentage of GagCM9-specific CD8
+ T cells that had five molecules (yellow), four molecules (orange), three molecules (green), two
molecules (red) or one molecule (blue). Animal r88085 was a Mamu-A*01
+ delta-nef-vaccinated, SIVsmE660-infected elite controller from a previous
study who mounted a GagCM9-specific CD8
+ T cell response.
doi:10.1371/journal.pone.0023515.g002
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vaccinated animals had a small percentage of GagCM9-specific
CD8
+ T cells that performed all five functions tested (Figure 2a
and b). This fraction of GagCM9-specific CD8
+ T cells
degranulated as measured by CD107a staining and secreted all
four tested molecules: MIP-1b, TNF-a, IFN-c, and IL-2. Less than
25% of GagCM9-specific CD8
+ T cells performed only one
function tested. Though slight differences were seen, six of the
seven vaccinated animals had a high percentage of GagCM9-
specific CD8
+ T cells that performed three or more measured
functions. Most of the GagCM9-specific CD8
+ T cell responses
from the seven vaccinated animals therefore secreted several
cytokines and were also comparable to the multifunctional
GagCM9-specific CD8
+ T cell response of r88085, an EC.
However, the GagCM9-specific CD8
+ T cells from the vaccinated
animals did not control viral replication.
GagCM9-specific CD8
+ T cells access the gut mucosa and
B cell follicles in lymph nodes
Because the high frequency, multifunctional GagCM9-specific
CD8
+ T cells did not reduce viral replication in vivo, we next
speculated that these cells might not be accessing the major sites of
infection, which would explain their inability to control viral
replication in SIV-producing cells. The gut mucosa is a primary
site of HIV and SIV infection [50,51]. At approximately fifteen
weeks post-infection we biopsied the gut of all seven animals and
extracted lymphocytes. GagCM9 tetramer staining of the colonic
lymphocytes showed that between 0.56%–3.88% of the CD3
+
lymphocytes were GagCM9-specific CD8
+ T cells (Figure 3a–g).
The presence of these cells in the gut during the chronic phase of
infection indicates that although recruited to one known site of
infection, they were still not capable of controlling viral replication.
Lymph nodes also have high concentrations of SIV-producing
cells; therefore, we next biopsied lymph nodes from the chronic
phase of infection to determine the localization and abundance of
GagCM9-specific CD8
+ T cells [52]. In situ GagCM9 tetramer
staining showed high concentrations of GagCM9-specific CD8
+ T
cells in the lymph nodes of five of the seven animals as well as the
presence of GagCM9-specific CD8
+ T cells in the B cell follicle
(Figure 4b, d, f, and g), the primary site of infected cells in the
lymph node ([53], Figure 4h). Although concentrated in the
extrafollicular regions of the lymph nodes, GagCM9-specific
CD8
+ T cells were found in relatively high concentrations within
the B cell follicles (Figure 4g). In situ hybridization of the lymph
nodes found SIV-producing cells concentrated inside the B cell
follicles with very few residing in the extrafollicular region
(Figure 4h). Comparing the abundance of GagCM9-specific
CD8
+ T cells with the quantity of SIV-producing cells inside the
B cell follicle of the lymph node samples from each animal showed
a high effector to target ratio of approximately 20–250 GagCM9-
specific CD8
+ T cells per SIV-producing cell (Figure 4g and h).
The effector to target ratio increased further when the total lymph
node tissue was examined. The inability of GagCM9-specific
CD8
+ T cells to access sites of infection did not, therefore, explain
the high viral loads in these animals.
Viral escape from the GagCM9-specific CD8
+ T cell
response does not account for the lack of viral control
Wenext hypothesized that GagCM9-specific CD8
+T cell pressure
had selected for viral escape soon after infection. If so, the GagCM9-
specific CD8
+ T cells would no longer be able to recognize SIV-
infected cells and therefore fail to control viral replication. However,
it has previously been shown that Gag-vaccinated rhesus macaques
did not select for viral escape in the GagCM9 epitope until 30 weeks
post-SIVsmE660 infection [54]. Additionally, in animals that initially
controlled SIVsmE660 infection, the emergence of escape mutations
in the GagCM9 epitope correlated with viral breakthrough [54]. To
examine the potential role of viral escape from the GagCM9-specific
CD8
+T cellresponse, we sequenced plasmafrom allseven animals at
weeks two, ten and 20 post-infection (Figure 5). The consensus
sequence of SIVsmE660 contains an isoleucine to valine amino acid
change at position 161 at the upstream compensatory GagCM9
mutation, I161V [55]. Besides this change, only virus from animal
r01056 contained amino acid variation at 20 weeks post-infection
(Figure 5a); a position two mixed base of threonine and serine. The
downstream compensatory GagCM9 position 206 isoleucine to
valine, I206V, mutation was not seen in any of the animals at any
Figure 3. GagCM9-specific CD8
+ T cells access the gut mucosa.
Gut biopsies were performed during the chronic phase of infection for
each animal. Harvested gut lymphocytes were stained for GagCM9 APC
tetramer, CD3 FITC and CD8 Pacific Blue. Each panel was gated on CD3
+
lymphocytes.
doi:10.1371/journal.pone.0023515.g003
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amplicons from each timepoint. At weeks two and ten post-infection,
the GagCM9 epitope from all animals contained no amino acid
variation (Figure S2). At week 20 post-infection, pyrosequencing
confirmed the position two threonine to serine substitution in r01056
with the mutation seen in approximately 50% of the viral population.
Less than 25% of the viral population from the other six animals at
week 20 post-infection contained an amino acid replacement in the
GagCM9 epitope (Figure S2). Viral escape, therefore, does not
explain the failure of the GagCM9-specific CD8
+ T cells to control
viral replication during both the acute and early chronic phases of
infection.
Vaccinated animals have few public TCR clonotypes
within the GagCM9-specific CD8
+ T cell population pre-
and post-infection
Thus far, we have determined that our cohort of vaccinated
animals have high frequency, multifunctional GagCM9-specific
CD8
+ T cells that accessed major sites of SIV infection, but yet
were still unable to control viral replication. The number of public
TCR clonotypes within the GagCM9-specific CD8
+ T cell
population may be inversely correlated with viral load [36].
Public clonotypes are defined as epitope-specific TCRb-chain
amino acid sequences that occur in more than one animal. Thus,
these are shared T cell receptors that represent an extreme bias in
TCR usage. We, therefore, hypothesized that our vaccinated
cohort would have few public TCR clonotypes within the
GagCM9-specific CD8
+ T cell population post-infection. Post-
vaccination and at four weeks post-infection, GagCM9-specific
CD8
+ T cells were sorted from PBMC from all seven vaccinated
animals. The TCRs expressed by these cells were then sequenced
and analyzed. Interestingly, five out of the seven animals did not
have any public clonotypes in the GagCM9-specific CD8
+ T cell
population post-vaccination and pre-infection (Figure 6a). Animal
r03130 had only one public clonotype, while r02049, the elite
controller animal, had two public clonotypes pre-infection. Post-
infection, all animals had GagCM9-specific CD8
+ T cells that
expressed public TCR clonotypes. T cells from these animals
expressed between one and five public clonotypes post-infection
with GagCM9-specific CD8
+ T cells from animals r02042 and
r02049 expressing five and four public clonotypes post-infection,
respectively. Interestingly, GagCM9-specific CD8
+ T cells from
animal r02042 expressed more public clonotypes than r02049, the
elite controller animal; however, r02042 failed to control viral
replication.
Few of the GagCM9-specific TCR clonotypes expressed post-
vaccination were maintained after infection. Only four of the
seven animals maintained GagCM9-specific TCR clonotypes after
infection. Only two of the eight maintained GagCM9-specific
TCR clonotypes in those four animals had frequencies greater
than 7% of the total TCR clonotypes post-infection. Additionally,
Figure 4. GagCM9-specific CD8
+ T cells reside in the lymph nodes of infected animals at high effector to target ratios. Representative
images of Mamu A*01-restricted GagCM9-specific tetramer positive CD8
+ T cells (red) and CD20
+ B cells (green) in lymph node sections taken during
the chronic phase of infection from animals r03130 (a, b), r04051 (e, f), and r04091 (c, d). B cell follicles are delineated with a white line. The images to
the right (b, d, f) show the same field as presented on the left (a, c, e) with only the red tetramer stain shown. Each tetramer-binding cell is indicated
with a white arrow. (g) The frequency of GagCM9-specific tetramer positive CD8
+ T cells per mm
2 inside and outside of the B cell follicle as well as
total tissue was calculated for each animal. (h) The frequency of SIV producing cells per mm
2 inside and outside the B cell follicle as well as total tissue
was calculated for each animal. Animals r02042 and r02049 did not have any positive cells in the sections examined.
doi:10.1371/journal.pone.0023515.g004
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specific TCR clonotype expanded post-infection. A TCR
clonotype from r02042 increased from 24% of the total
GagCM9-specific TCR population post-vaccination to 44%
post-infection. Interestingly, there was a statistically significant
inverse correlation between the number of public clonotypes
expressed by GagCM9-specific CD8
+ T cells post-infection and
chronic phase viral load (Figure 6b, p=0.0213). Animals that had
three, four, or five public TCR clonotypes specific for GagCM9
post-infection had significantly lower week 16 viral loads than
animals with only one or two public TCR clonotypes. Though all
animals had at least one public GagCM9-specific TCR clonotype
expressed post-infection, our data indicate that the limited TCR
repertoire within the GagCM9-specific CD8
+ T cell response
might be a contributing factor for the lack of control of viral
replication.
Discussion
In a previous study [37], we vaccinated seven Mamu-A*01
+
rhesus macaques with rYF-17D/SIVGag45–269. After infection
with the swarm SIVsmE660 virus, six of the seven animals failed to
control viral replication. No control of acute phase viral replication
was observed in any animal, while only r02049 controlled viral
replication during the chronic phase of infection. Additionally,
there were no differences between the vaccinated group mean viral
load and the viral loads of the two mock-vaccinated Mamu-A*01
+
control animals. Interestingly, however, all vaccinated animals
made high frequency, anamnestic GagCM9-specific CD8
+ T cell
responses that dominated the anti-SIV immune response in all
animals (Figure S3). More than 7% of the CD3
+CD8
+ T cells were
specific for the GagCM9 epitope. These GagCM9-specific CD8
+
T cells were multifunctional, that is greater than 75% of GagCM9-
specific CD8
+ T cells in each animal degranulated and secreted
several molecules simultaneously. Additionally, the GagCM9-
specific CD8
+ T cells from all animals accessed the gut mucosa as
well as B cell follicles in the lymph node, the primary residences of
SIV-producing cells. The number of public TCR clonotypes
expressed by the GagCM9-specific CD8
+ T cell populations of this
cohort, however, significantly inversely correlated with chronic
phase viral load.
HIV-infected ECs have multifunctional HIV-specific CD8
+ T
cells as compared to HIV-infected progressors [32]. This implies
that maintaining HIV/SIV-specific CD8
+ T cells capable of
concomitantly secreting IFN-c, TNF-a, IL-2, and MIP-1b and
upregulating cell surface expression of CD107a may be critical to
reducing viral loads in vivo. SIVsmE660 infection induced
multifunctional GagCM9-specific CD8
+ T cells comparable to
those from a delta-nef-vaccinated, SIVsmE660-infected EC;
however, these cells failed to control viral replication. The
multifunctional profile of the GagCM9-specific CD8
+ T cells
from the EC in this study, r02049, was very similar to the
multifunctional profiles of r01056 and r03130, two animals with
high viral loads. Though the ability of HIV/SIV-specific CD8
+ T
cells to secrete several cytotoxic molecules and degranulate
simultaneously likely plays a role in reducing viral replication,
our study indicates that despite the presence of these types of
antigen-specific CD8
+ T cells, viral replication continued unabat-
ed.
A previous study has suggested that SIV-specific CD8
+ T cells
only partially controlled viral replication because they expanded
too late after SIVmac239 infection and were low or undetectable
in the gut mucosa [56]. Even though the vaccine-induced
GagCM9-specific CD8
+ T cells in our current study expanded
to high frequencies by two weeks post-SIVsmE660 infection, the
SIV-specific CD8
+ T cell response may have simply arrived too
late to control viral replication and prevent CD4
+ T cell loss in the
gut mucosa. Additionally, while the decline of peak viremia was
concomitant with the expansion of GagCM9-specific CD8
+ T
cells, the reduction of peak viremia in these animals may have
been due to other factors such as the loss of targets cells, other
SIV-specific CD8
+ T cells, SIV-specific CD4
+ T cells, innate
features, etc.
The inability of GagCM9-specific CD8
+ T cells to control viral
replication in vivo may be due to the lack of vaccine- and infection-
induced public TCR clonotypes within the GagCM9-specific
CD8
+ T cell population. Public TCR clonotypes expressed by
GagCM9-specific CD8
+ T cells were seen pre-infection in only
two vaccinated animals: two public TCR clonotypes in r02049
and one in r03130. An average of 2.5 public TCR clonotypes in
the GagCM9-specific CD8
+ T cell population were elicited after
SIVsmE660 infection. In fact, the number of public TCR
clonotypes present at week 3 post-infection significantly correlated
with the week 16 viral load. A similar earlier study analyzed the
frequency of public TCR clonotypes in the GagCM9-specific
CD8
+ T cell population elicited by a DNA/Ad5 prime/boost
vaccination regimen encoding SIVmac239 Gag, Tat, Rev, and
Nef of Mamu-A*01
+ SIVmac239-infected macaques [36]. More
public TCR clonotypes were elicited in the GagCM9-specific
CD8
+ T cell population after vaccination and after infection than
in our current study, particularly in animals that controlled viral
replication. ECs in this previous study had an average of four
public TCR clonotypes after vaccination and almost seven public
TCR clonotypes after infection. The correlation data from the
Figure 5. Viral sequencing of Gag containing the GagCM9 CD8
epitope and its known compensatory mutation amino acid
locations showed little viral escape. (a–g) We performed bulk viral
Sanger sequencing at weeks two, ten, and twenty post-infection of the
GagCM9 epitope and surrounding amino acids. The SIVsmE660 stock
contains the isoleucine to valine GagCM9 upstream compensatory
mutation at position 161, which all animals maintained throughout the
acute and chronic phases of infection. Dots indicate no amino acid
deviation from SIVmac239. Animal r02049 had no detectable virus at
week 20; therefore, its virus could not be sequenced.
doi:10.1371/journal.pone.0023515.g005
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consistent with similar slopes (20.55 versus 20.63) and r
2 values
(0.66 versus 0.69) when we compare the number of public TCR
clonotypes elicited in the GagCM9-specific CD8
+ T cell
population of vaccinated animals with chronic phase viral load.
CD8
+ T cells with public TCR clonotypes expand quickly upon
antigen stimulation and it has been suggested that public TCR
clonotypes may have increased recognition of epitope variants
compared to private TCR clonotypes [36,57,58]. The inability of
our vaccinated animals to control viral replication in vivo may,
therefore, have been due to the paucity of public TCR clonotypes
expressed by the GagCM9-specific CD8
+ T cell population.
It is difficult to understand why such high frequencies of
GagCM9-specific CD8
+ T cells had no effect on viral replication.
Animal r01056 had approximately 40% of its CD3
+CD8
+ T cells
directed against the virus during the acute phase, yet there was no
effect on viremia. High concentrations of an effective antiretroviral
drug would have resulted in control of viral replication with
subsequent escape. Escape from the GagCM9-specific CD8
+ T
cell response did not occur until week 20 post-infection in r01056
and its GagCM9 epitope was intact at weeks two and ten post-
infection. It might be argued that the breadth of the CD8
+ T cell
response is important [5,26,28,59,60] and that 20 different low
frequency CD8
+ T cell responses against several epitopes would
have been more effective than a single high frequency CD8
+ T cell
response. This would be understandable if the GagCM9 epitope
had escaped early, but this was not the case. One implication of
this result could be that some CD8
+ T cell responses are more
efficacious than others. This would, therefore, be epitope-
dependent since the GagCM9-specific CD8
+ T cell responses in
this study appeared to be effective by all of our classical
measurements. Finally, our data suggest that the GagCM9-specific
CD8
+ T cell popoulations from the rYF-17D/SIVGag45–269-
vaccinated, SIVsmE660-infected animals failed to reduce viral
replication due to the limited public TCR repertoires elicited by
the GagCM9-specific CD8
+ T cell populations post-infection.
Inducing several public TCR clonotypes in CD8
+ T cell
populations via vaccination that are maintained after infection
may, therefore, be efficacious in reducing acute and chronic phase
viral loads.
Supporting Information
Figure S1 Viral load and GagCM9-specific CD8
+ T cell
tetramer staining for each animal. (a–g) Plasma viral RNA
content was measured by quantitative PCR from weeks 0 to 48
post-infection for all vaccinated animals, black diamonds and
connecting line. The percentage of CD3
+CD8
+ GagCM9-specific
T cells were enumerated using GagCM9-specific tetramers at each
indicated timepoint, red triangles and connecting line. (h, i) Plasma
viral RNA content (black diamonds and connecting line) and the
percentage of CD3
+CD8
+ GagCM9-specific T cells (blue
diamonds and connecting line) were calculated at each timepoint
from the two mock-vaccinated, SIVsmE660-infected control
animals. (j) The group mean viral load (black diamonds and
connecting line) and GagCM9-specific CD8
+ T cell tetramer
percentage (red triangles and connecting line) of the seven
vaccinated, SIVsmE660-infected animals were calculated.
(TIF)
Figure S2 Pyrosequencing revealed less than 25% of
viral populations exhibit GagCM9 escape in six of the
seven animals. Pyrosequencing was performed at weeks two,
ten and twenty post-infection of the GagCM9 epitope and
surrounding regions. We were unable to sequence virus from
r02042 at week twenty and r02049 at weeks ten and twenty due to
low or undetectable viral loads. Only r01056 had escape within
the GagCM9 epitope at one timepoint in greater than 25% of viral
populations.
(TIF)
Figure S3 Post-infection whole PBMC IFN-c ELISPOT.
Week three (a) and ten (b) post-infection whole PBMC IFN-c
ELISPOT heat maps indicate responses to peptide pools detected
at each timepoint. Green squares indicate 50–200 spot forming
cells (SFCs)/million PBMC, blue squares indicate 201–500 SFCs/
million PBMC, yellow squares indicate 501–1000 SFCs/million
PBMC, orange squares indicate 1001–2000 SFCs/million PBMC,
and red squares indicate greater than 2001 SFCs/million PBMC.
T: Tat; R: Rev; V: Vpr; X: Vpx; *: GagCM9; ‘: GagQI9.
GagCM9 was also located in the Gag E peptide pool.
(TIF)
Acknowledgments
The following reagent was obtained through the NIH AIDS Reagent and
Reference Reagent Program, Division of AIDS, NIAID, NIH: IL-2,
human (item no. 136) from Hoffman-La Roche.
The authors would also like to acknowledge Shari Piaskowski and Jessica
Furlott for technical assistance; Caitlin McNair, Jennifer Nelson, and
Thomas Friedrich for viral load analysis; and William Rehrauer, Chrystal
Glidden, Gretta Borchardt, and Debra Fisk for MHC typing of animals.
Author Contributions
Conceived and designed the experiments: LV MAM DIW. Performed the
experiments: LV JRA ZE MRR EJL KLW BJB JMF MGVdS PCCN PJS
EG DHO NAW MCB RG DAP. Analyzed the data: LV JRA EGR EC
PJS DCD. Wrote the paper: LV DIW.
References
1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific
CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in
primary human immunodeficiency virus type 1 infection. J Virol 68: 6103–6110.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal
association of cellular immune responses with the initial control of viremia in
primary human immunodeficiency virus type 1 syndrome. J Virol 68:
4650–4655.
3. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, et al. (1999)
Emergence of CTL coincides with clearance of virus during primary simian
immunodeficiency virus infection in rhesus monkeys. J Immunol 162:
5127–5133.
4. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, et al.
(1994) Immunopathogenic events in acute infection of rhesus monkeys with
simian immunodeficiency virus of macaques. J Virol 68: 2362–2370.
Figure 6. GagCM9-specific CD8
+ T cell receptor clonal analysis. (a) TCRb CDR3 sequences, TCRbV and TCRbJ usage, and the relative frequency
of TCR clonotypes in the GagCM9-specific CD8
+ T cell population were analyzed for each animal after vaccination and three weeks after infection.
Colored boxes in the CDR3 column indicate public TCR clonotypes (GagCM9-specific TCRb-chain amino acids that occur in more than one Mamu-
A*01
+ rhesus macaque), while colored boxes in the frequency column indicate TCR clonotypes that were maintained from post-vaccination to post-
infection. (b) The week 16 viral load from each animal was correlated with the number of public TCR clonotypes within the GagCM9-specific CD8
+ T
cell population present at week three post infection.
doi:10.1371/journal.pone.0023515.g006
GagCM9-Specific CTL Do Not Suppress SIV In Vivo
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e235155. Friedrich TC, Valentine LE, Yant LJ, Rakasz EG, Piaskowski SM, et al. (2007)
Subdominant CD8+ T-cell responses are involved in durable control of AIDS
virus replication. J Virol 81: 3465–3476.
6. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise in
plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-
infected macaques. J Exp Med 189: 991–998.
7. Matano T, Shibata R, Siemon C, Connors M, Lane HC, et al. (1998)
Administration of an anti-CD8 monoclonal antibody interferes with the
clearance of chimeric simian/human immunodeficiency virus during primary
infections of rhesus macaques. J Virol 72: 164–169.
8. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, et al. (1999)
Control of viremia in simian immunodeficiency virus infection by CD8+
lymphocytes. Science 283: 857–860.
9. Allen TM, O’Connor DH, Jing P, Dzuris JL, Mothe ´ BR, et al. (2000) Tat-
specific cytotoxic T lymphocytes select for SIV escape variants during resolution
of primary viraemia. Nature 407: 386–390.
10. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, et al. (2002)
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic
T lymphocytes. Nature 415: 335–339.
11. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral
pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during
primary infection demonstrated by rapid selection of CTL escape virus. Nat
Med 3: 205–211.
12. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, et al. (2001)
Evolution and transmission of stable CTL escape mutations in HIV infection.
Nature 412: 334–338.
13. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late
escape from an immunodominant cytotoxic T-lymphocyte response associated
with progression to AIDS. Nat Med 3: 212–217.
14. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, et al. (1995) Transfer of
HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for
mutant HIV variants and subsequent disease progression. Nat Med 1: 330–336.
15. O’Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, et al. (2002) Acute
phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency
virus infection. Nat Med 8: 493–499.
16. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, et al. (1991)
Human immunodeficiency virus genetic variation that can escape cytotoxic T
cell recognition. Nature 354: 453–459.
17. Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, et al.
(1996) Adaptive evolution of human immunodeficiency virus-type 1 during the
natural course of infection. Science 272: 537–542.
18. Kaslow RA, Carrington M, Apple R, Park L, Mun ˜oz A, et al. (1996) Influence of
combinations of human major histocompatibility complex genes on the course of
HIV-1 infection. Nat Med 2: 405–411.
19. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004)
Dominant influence of HLA-B in mediating the potential co-evolution of HIV
and HLA. Nature 432: 769–775.
20. Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, et al. (2007) Mamu-
B*08-positive macaques control simian immunodeficiency virus replication.
J Virol 81: 8827–8832.
21. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al.
(2000) HLA B*5701 is highly associated with restriction of virus replication in a
subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA
97: 2709–2714.
22. Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, et al. (2006) The
high-frequency major histocompatibility complex class I allele Mamu-B*17 is
associated with control of simian immunodeficiency virus SIVmac239
replication. J Virol 80: 5074–5077.
23. Allen TM, Jing P, Calore B, Horton H, O’Connor DH, et al. (2002) Effects of
cytotoxic T lymphocytes (CTL) directed against a single simian immunodefi-
ciency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.
J Virol 76: 10507–10511.
24. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, et al. (1999) In
vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat
Med 5: 34–41.
25. Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, et al. (2008)
Gag-Specific Cytotoxic T-Lymphocyte-Based Control of Primary Simian
Immunodeficiency Virus Replication in a Vaccine Trial. J Virol 82:
10199–10206.
26. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al.
(2007) CD8+ T-cell responses to different HIV proteins have discordant
associations with viral load. Nat Med 13: 46–53.
27. Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, et al. (2005) Vectored
Gag and Env but not Tat show efficacy against simian-human immunodefi-
ciency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol
79: 12321–12331.
28. Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune
control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature
457: 87–91.
29. Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, et al. (2007) Gag-
specific CD8+ T lymphocytes recognize infected cells before AIDS-virus
integration and viral protein expression. J Immunol 178: 2746–2754.
30. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, et al. (2006)
Vaccine-induced cellular immune responses reduce plasma viral concentrations
after repeated low-dose challenge with pathogenic simian immunodeficiency
virus SIVmac239. J Virol 80: 5875–5885.
31. Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, et al. (2007) Pol-specific CD8+
T cells recognize simian immunodeficiency virus-infected cells prior to Nef-
mediated major histocompatibility complex class I downregulation. J Virol 81:
11703–11712.
32. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV
nonprogressors preferentially maintain highly functional HIV-specific CD8+ T
cells. Blood 107: 4781–4789.
33. Horton H, Frank I, Baydo R, Jalbert E, Penn J, et al. (2006) Preservation of T
cell proliferation restricted by protective HLA alleles is critical for immune
control of HIV-1 infection. J Immunol 177: 7406–7415.
34. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, et al. (2004) Loss of
HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and
restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 200:
701–712.
35. Migueles S, Osborne C, Royce C, Compton A, Joshi R, et al. (2008) Lytic
Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell
Elimination Associated with Immune Control. Immunity 29: 1009–1021.
36. Price D, Asher T, Wilson N, Nason M, Brenchley J, et al. (2009) Public
clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV
infection. Journal of Experimental Medicine 206: 923–936.
37. Bonaldo MC, Martins MA, Rudersdorf R, Mudd PA, Sacha JB, et al. (2010)
Recombinant yellow fever vaccine virus 17D expressing simian immunodefi-
ciency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in
rhesus macaques. J Virol 84: 3699–3706.
38. Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, et al. (2007)
Molecular typing of major histocompatibility complex class I alleles in the Indian
rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 59:
693–703.
39. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, et al. (2004)
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med
10: 275–281.
40. Friedrich TC, McDermott AB, Reynolds MR, Piaskowski S, Fuenger S, et al.
(2004) Consequences of cytotoxic T-lymphocyte escape: common escape
mutations in simian immunodeficiency virus are poorly recognized in naive
hosts. J Virol 78: 10064–10073.
41. Bimber BN, Burwitz BJ, O’Connor S, Detmer A, Gostick E, et al. (2009)
Ultradeep pyrosequencing detects complex patterns of CD8+ T-lymphocyte
escape in simian immunodeficiency virus-infected macaques. J Virol 83:
8247–8253.
42. Cline AN, Bess JW, Piatak M, Lifson JD (2005) Highly sensitive SIV plasma viral
load assay: practical considerations, realistic performance expectations, and
application to reverse engineering of vaccines for AIDS. J Med Primatol 34:
303–312.
43. Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, et al. (2003)
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-
phase viral replication but fail in long-term control of simian immunodeficiency
virus SIVmac239. J Virol 77: 13348–13360.
44. Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT (2000) Cutting
edge: In situ tetramer staining of antigen-specific T cells in tissues. J Immunol
165: 613–617.
45. Folkvord JM, Anderson DM, Arya J, Mawhinney S, Connick E (2003)
Microanatomic relationships between CD8+ cells and HIV-1-producing cells in
human lymphoid tissue in vivo. J Acquir Immune Defic Syndr 32: 469–476.
46. Allen TM, Mothe ´ BR, Sidney J, Jing P, Dzuris JL, et al. (2001) CD8(+)
lymphocytes from simian immunodeficiency virus-infected rhesus macaques
recognize 14 different epitopes bound by the major histocompatibility complex
class I molecule mamu-A*01: implications for vaccine design and testing. J Virol
75: 738–749.
47. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and
protection: implications for vaccine design. Nat Rev Immunol 8: 247–258.
48. Roederer M, Nozzi JL, Nason MC (2011) SPICE: Exploration and analysis of
post-cytometric complex multivariate datasets. Cytometry A 79A: 167–174.
49. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, et al.
(2008) Macaques vaccinated with live-attenuated SIV control replication of
heterologous virus. J Exp Med 205: 2537–2550.
50. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+
T cell depletion during all stages of HIV disease occurs predominantly in the
gastrointestinal tract. J Exp Med 200: 749–759.
51. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al. (1998)
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral
replication in SIV infection. Science 280: 427–431.
52. Vanderford T, Bleckwehl C, Engram JC, Dunham RM, Klatt N, et al. (2011)
Viral CTL Escape Mutants Are Generated in Lymph Nodes and Subsequently
Become Fixed in Plasma and Rectal Mucosa during Acute SIV Infection of
Macaques. PLoS Pathog 7: e1002048.
53. Folkvord JM, Armon C, Connick E (2005) Lymphoid follicles are sites of
heightened human immunodeficiency virus type 1 (HIV-1) replication and
reduced antiretroviral effector mechanisms. AIDS Res Hum Retroviruses 21:
363–370.
54. Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, et al.
(2003) Viral escape from dominant simian immunodeficiency virus epitope-
GagCM9-Specific CTL Do Not Suppress SIV In Vivo
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23515specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 77:
7367–7375.
55. Friedrich TC, Frye CA, Yant LJ, O’Connor DH, Kriewaldt NA, et al. (2004)
Extraepitopic compensatory substitutions partially restore fitness to simian
immunodeficiency virus variants that escape from an immunodominant
cytotoxic-T-lymphocyte response. J Virol 78: 2581–2585.
56. Reynolds MR, Rakasz E, Skinner PJ, White C, Abel K, et al. (2005) CD8+ T-
lymphocyte response to major immunodominant epitopes after vaginal exposure
to simian immunodeficiency virus: too late and too little. J Virol 79: 9228–9235.
57. Venturi V, Chin HY, Price DA, Douek DC, Davenport MP (2008) The role of
production frequency in the sharing of simian immunodeficiency virus-specific
CD8+ TCRs between macaques. J Immunol 181: 2597–2609.
58. Venturi V, Price DA, Douek DC, Davenport MP (2008) The molecular basis for
public T-cell responses? Nat Rev Immunol 8: 231–238.
59. Loffredo JT, Bean AT, Beal DR, Leo ´n EJ, May GE, et al. (2008) Patterns of
CD8+ immunodominance may influence the ability of Mamu-B*08-positive
macaques to naturally control simian immunodeficiency virus SIVmac239
replication. J Virol 82: 1723–1738.
60. Martins MA, Wilson NA, Reed JS, Ahn CD, Klimentidis YC, et al. (2010) T-cell
correlates of vaccine efficacy after a heterologous simian immunodeficiency virus
challenge. J Virol 84: 4352–4365.
GagCM9-Specific CTL Do Not Suppress SIV In Vivo
PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e23515